Our guest today introduced us to a new kind of immunotherapy called Super-NK. Imagine CAR-T, but in this case, the immune cells from the patient are not engineered, but rather “supercharged.” What’s remarkable is that the company is having success with the therapy against neurological conditions such as Alzheimer’s and Parkinson's.Paul Song is the CEO of NKGen Biotech.